A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders
Science Advances · 2026
DOI: 10.1126/sciadv.aed3119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Justin Y Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences & Toxicology, University of California, Berkeley, CA 94720, USA. Hauptthemen laut MEDLINE: Obesity, Lipid Metabolism, Energy Metabolism, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Liver Center, University of California, San Francisco, NIH/NIDDK.
Abstract (Originalsprache)
Obesity and related metabolic disorders have surged globally, and are mechanistically interconnected through dysregulated energy and lipid metabolism pathways. Current incretin-based obesity treatments act to decrease food intake, but are associated with gastrointestinal side effects and muscle wasting. Here, we identified an orally bioavailable multi-functional small molecule, 5-tetradecyloxy-2-furoic acid (TOFA), that promotes energy expenditure and rebalances lipid synthesis, thereby significantly alleviating obesity, abnormal glucose homeostasis and fatty liver-related diseases without affecting food intake or muscle mass. Mechanistically, TOFA inhibits the lipogenic enzymes acetyl-CoA carboxylases 1 and 2 (ACC1/2) and activates the Peroxisome Proliferator-Activated Receptors alpha and delta (PPARα/δ), key regulators of energy expenditure and lipid metabolism gene expression programs. TOFA acted more than additively with incretin analogs such as semaglutide and tirzepatide to improve obesity, dyslipidemia, and insulin resistance. Our findings suggest that the coordinated multi-targeting of energy metabolism and lipid homeostasis by TOFA is an effective approach to address multiple associated metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences & Toxicology, University of California, Berkeley, CA 94720, USA.
- Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
- Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Center Munich, 04103 Leipzig, Germany.
- ReRx Therapeutics, Inc., Berkeley, CA 94704, USA.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston MA 02114, USA.
ORCID-Profile: Justin Y Lee, Chi Zhu, Melissa A Boldridge, Rachelle L Stark, Kosuke Watari, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T Dang, Kook Son, Ruslan I Sadreyev, Bilal N Sheikh, Michael Karin, Anders M Näär
Förderung
- NIDDK NIH HHS
- Liver Center, University of California, San Francisco
- NIH/NIDDK
- University of Michigan Animal Phenotyping Core
Zitieren
APA
Lee, J. Y., Zhu, C., Boldridge, M. A., Stark, R. L., Bonilla, G., Watari, K., Papa, C., Xu, L., Gonzalez, F., Tang, X., Dang, K. T., Son, K., Chetal, K., Ibrahim, P., Sadreyev, R. I., Sheikh, B. N., Karin, M., & Näär, A. M. (2026). A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders. Science Advances. https://doi.org/10.1126/sciadv.aed3119
Vancouver
Lee JY, Zhu C, Boldridge MA, Stark RL, Bonilla G, Watari K, et al. A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders. Science Advances. 2026. doi:10.1126/sciadv.aed3119
BibTeX
@article{Lee2026,
author = {Lee, Justin Y and Zhu, Chi and Boldridge, Melissa A and Stark, Rachelle L and Bonilla, Gracia and Watari, Kosuke and Papa, Christina and Xu, Lei and Gonzalez, Federico and Tang, Xin and Dang, Kaitlyn T and Son, Kook and Chetal, Kashish and Ibrahim, Prabha and Sadreyev, Ruslan I and Sheikh, Bilal N and Karin, Michael and Näär, Anders M},
title = {A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed3119}
}
EUVIMED